Abstract A232: In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori.
Elena Ardini(Nerviano Medical Sciences), Arturo Galvani(Nerviano Medical Sciences), Nilla Avanzi(Nerviano Medical Sciences), Daniele Donati(Nerviano Medical Sciences), Maria Menichincheri(Nerviano Medical Sciences), Patrizia Banfi(Nerviano Medical Sciences), Antonella Isacchi(Nerviano Medical Sciences), Daniele Casero(Nerviano Medical Sciences), Maria Beatrice Saccardo(Nerviano Medical Sciences), Luisa Rusconi(Nerviano Medical Sciences), Enrico Pesenti, Sabrina Cribioli(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia)
Cited by 20
Related Papers
Discovery of drug mode of action and drug repositioning from transcriptional responses
|Proceedings of the National Academy of Sciences|2010|853
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205
The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
|Molecular Oncology|2014|156
Divergent effects of RIP1 or RIP3 blockade in murine models of acute liver injury
|Cell Death and Disease|2015|129